Albert Joseph, MD
General Practice · Fair Lawn, NJNPI 1518051499
Payments from drug & device makers
Across 234 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$738
- Novo Nordisk$717
- Amgen$408
- Pfizer$282
- Sanofi-aventis U.S. LLC$218
- Exact Sciences$158
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,912100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 45 | $738 |
| Novo Nordisk | 46 | $717 |
| Amgen | 20 | $408 |
| Pfizer | 20 | $282 |
| Sanofi-aventis U.S. LLC | 15 | $218 |
| Exact Sciences | 7 | $158 |
| Madrigal Pharmaceuticals | 1 | $148 |
| AstraZeneca | 10 | $144 |
| Lilly USA, LLC | 10 | $138 |
| Philips North America LLC | 9 | $135 |
| Actelion Pharmaceuticals US, Inc. | 4 | $112 |
| Boehringer Ingelheim | 7 | $98 |
| GSK | 6 | $86 |
| Amarin Pharma, Inc. | 6 | $82 |
| Abbott | 3 | $66 |
| Xeris Pharmaceuticals, Inc. | 4 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $56 |
| Mylan Specialty L.p. | 3 | $49 |
| Johnson & Johnson | 2 | $36 |
| Viatris Specialty LLC | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,912 in reported general payments places this provider in the 95th percentile of 2,978 general practice providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 90 | $94,807 |
| JanuviaSitagliptin Phosphate | 71 | $68,943 |
| EliquisApixaban | 64 | $53,921 |
| Diclofenac Sodium | 72 | $51,769 |
| FarxigaDapagliflozin Propanediol | 33 | $33,271 |
| RybelsusSemaglutide | 25 | $32,756 |
| ProliaDenosumab | 17 | $31,172 |
| TradjentaLinagliptin | 13 | $18,665 |
| OzempicSemaglutide | 17 | $15,786 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $12,918 |
| VascepaIcosapent Ethyl | 14 | $7,642 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $7,472 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 30 | $7,009 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,888 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $5,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $98 | $113,472103 claims |
| MerckJanuvia, Janumet | $738 | $81,86286 claims |
| PfizerEliquis | $282 | $53,92164 claims |
| Novo NordiskRybelsus, Ozempic | $717 | $48,54242 claims |
| AstraZenecaFarxiga | $144 | $33,27133 claims |
| AmgenProlia | $408 | $31,17217 claims |
| GSKAnoro Ellipta | $86 | $6,88815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,978 general practice providers in New Jersey.
Other general practice in Fair Lawn
- Ryan LakeClark$914K
- Hua-Yu Steven LiaoLodi$816K
- Howard GlazerFort Lee$636K
- Frank LeeBradley Beach$417K
- Jeffrey ChustckieSomerset$165K
- John MinichettiEnglewood$142K
- Narenderan RajanHackettstown$135K
- Cindy YeungPiscataway$111K
- Andrew SpectorHaworth$75K
- Douglas BorkowskiHaskell$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.